Agenus advances portfolio with 6 clinical collaborations

Lexington, mass., may 31, 2022 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that it has entered into 3 new clinical collaborations with targovax, oxford biotherapeutics, and immunogenesis, doubling its current number of clinical collaborations. these 6 collaborations span a range of agenus' clinical assets, including botensilimab (fc-enhanced anti-ctla-4), balstilimab (anti-pd-1), zalifrelimab (anti-ctla-4), and qs-21 stimulon™.
AGEN Ratings Summary
AGEN Quant Ranking